Stock listing
Alzamend Neuro, Inc.
Selected listing: ALZN · NASDAQ · USD · US
Alzamend Neuro, Inc. (NASDAQ:ALZN), Health Technology. Latest release Aug 20, 2026: Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster…
- Ticker
- NASDAQ:ALZN
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc. is a public company traded under the ticker ALZN in the American market. Alzamend Neuro focuses on developing innovative therapies for neurological conditions.
Latest news from Alzamend Neuro, Inc.
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
August 20, 2026
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
August 4, 2026
Alzamend Neuro : Annual Report for Fiscal Year Ending April 30, 2026 (Form 10-K)
July 22, 2026
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
April 6, 2026
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
March 25, 2026
Research Alzamend Neuro, Inc.
Alzamend Neuro, Inc. company profile
View the public company page for Alzamend Neuro, Inc. on 6ix.
Alzamend Neuro, Inc. news
Read company news and market updates connected to Alzamend Neuro, Inc..
Alzamend Neuro, Inc. investor events
Find investor webinars, events, and replay context for Alzamend Neuro, Inc..